Glucowin-M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to release insulin, thereby enhancing glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. This dual-action formulation provides complementary mechanisms to effectively lower blood glucose levels in patients inadequately controlled by diet and exercise alone. Glucowin-M 2 Tablet PR is indicated for adults with type 2 diabetes who require combination therapy to achieve optimal glycemic targets. It should be used alongside lifestyle modifications, including diet and physical activity. The extended-release formulation allows for improved patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with metformin. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Contraindications include type 1 diabetes, diabetic ketoacidosis, and known hypersensitivity to either component. Proper adherence to prescribed dosage and medical supervision is essential to maximize therapeutic benefits and minimize adverse effects.

Dosage & How to Use